Essais liés9clinical trials
VilleIrvinelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07789015

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
BBP-418 (ribitol) Myopathies Phase 3 NCT05775848 Fortify — Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) ACTIVE_NOT_RECRUITING
FT819 Lupus Phase 2 NCT07570862 RECLAIM-LN — A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis RECRUITING
Nerandomilast Myopathies Phase 3 NCT07789015 VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies NOT_YET_RECRUITING
Pozelimab + Cemdisiran Myasthénie Phase 3 NCT05070858 NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Ofatumumab approved dose SEP Phase 3 NCT06869785 FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab ACTIVE_NOT_RECRUITING
Remibrutinib oral treatment SEP Phase 3 NCT06846281 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. RECRUITING
Ocrelizumab SEP Phase 3 NCT04548999 GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) ACTIVE_NOT_RECRUITING
Descartes-08 Myasthénie Phase 2 NCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING